Having developed the first Chinese domestic insulin analog, Gan & Lee has a complete R&D pipeline for insulin and related products. Currently, we have five recombinant insulin analogs commercialized and one human insulin injection approved in China. Our products cover the three sub-markets of insulin, namely long-acting, fast-acting and mixed insulin, and we are dedicated to providing more and better insulin therapeutic options to patients globally.

We are also actively engaged in the development of medicinal products in related fields. GZR18， an innovative therapeutic biological product, has begun the phase I clinical trial in China and the US.

Gan & Lee develops medical devices to support the treatment of diabetes. GanleeFine®, an injection pen needle for insulin received clearance from the U.S. Food and Drug Administration (FDA).

We hope to develop a new generation of cloud data management of blood glucose monitoring and insulin injection products through the combination of “Internet Plus”, a model of online medical service so that we can bring more convenient, better therapeutic options to diabetic patients globally.